207_Combined course Presentations

5FU/CDDP ± Cetuximab: SCOPE Trial

Phase II/III trial: RT-CT: Cisplatin 60 mg/m2 D1+ capecitabine: 625mg/m2 twice daily 4 cycles – RT 50 Gy during cycles 3&4 ± Cetuximab: 400 mg/m2 D1 then 250 mg/m2 weekly

Crosby, Lancet Oncol 2013; 14: 627–37